Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Core Insights - Pharvaris presented data on deucrictibant, an oral bradykinin B2 receptor antagonist, demonstrating its effectiveness in treating hereditary angioedema (HAE) attacks, with 78.6% of participants experiencing substantial symptom resolution within 24 hours [1][2] Group 1: Clinical Efficacy - Deucrictibant achieved substantial symptom resolution in 78.6% of participants within 24 hours after a single dose, compared to 22.4% for placebo [2] - The Treatment Outcome Score (TOS) questionnaire indicated that the majority of HAE attacks treated with deucrictibant resulted in significant symptom improvement [2] - The effectiveness of deucrictibant was found to be comparable to high-efficacy injectable therapies, with higher satisfaction scores than other oral prophylactic treatments [4] Group 2: Safety and Satisfaction - The treatment satisfaction questionnaire showed that participants reported higher satisfaction with deucrictibant's effectiveness compared to placebo, driven by favorable scores across all measured subdomains [4] - The side effects and convenience scores were consistent between deucrictibant and placebo, indicating a favorable safety profile [4] Group 3: Future Developments - Pharvaris plans to publish data from ongoing open-label extensions to further establish the long-term safety and efficacy of deucrictibant [2] - The company is exploring additional indications and pipeline expansion opportunities to address unmet needs in the HAE community [2][5] Group 4: Product Information - Deucrictibant is being developed in two formulations: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic use [6] - The company aims to provide effective, safe, and easy-to-administer alternatives for all sub-types of HAE [7]